Obtained the Drug Registration Certificate for Taijilidine Fumarate Injection
March 18, 2025
Source: drugdu
42
On March 16, Hengrui Medicine (600276.SH) announced that the company received the "Drug Registration Certificate" for Taijilidine Fumarate Injection approved and issued by the National Medical Products Administration, approving the company's independently developed Class 1 innovative drug Taijilidine Fumarate Injection to add new indications and merge and revise the instructions. The indication is for the treatment of moderate to severe postoperative pain. The drug is a μ opioid receptor-biased small molecule agonist, which was approved for marketing in China in January 2024. It is suitable for moderate to severe pain after abdominal surgery and is China's first independently developed Class 1 opioid analgesic innovative drug. As of now, the cumulative R&D investment in related projects is approximately RMB 197.91 million.
https://finance.eastmoney.com/a/202503163346884091.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- JSKN003 Receives Breakthrough Therapy Designation in China March 19, 2025
- Shapuaisi obtains drug registration certificate for tafluprost eye drops March 19, 2025
- Huiyu Pharmaceuticals Obtains Drug Registration Certificate for Melphalan Hydrochloride March 19, 2025
- Two drugs were included in the “Rare Disease Drug Development “Care Plan” March 19, 2025
- First proof, first installment! Two medical devices approved for market launch March 18, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
